Kailera/Hengrui’s Oral GLP-1 Looks Effective, But GI Toxicity Raises Concern
Trials of the oral GLP-1 receptor agonist in overweight and obesity showed promising efficacy, but with much higher rates of nausea and vomiting than with Foundayo or Wegovy pill.
Scrip - July 7, 2026

FDA Electronic Labeling Proposal Could Reshape Medical Device Instructions For Use
The FDA is proposing a rule that would allow device manufacturers to replace paper instructions for use with electronic labels. The proposal — part of the federal 2026 Unified Agenda — targets an NPRM publication in November 2026 and is expected to reduce regulatory burden on the industry.
Medtech Insight - July 7, 2026

Compass Sets Course For 2027 COMP360 Launch In Resistant Depression
New Phase III data show the psychedelic yielded durable efficacy through at least six months, reinforcing earlier efficacy data in treatment-resistant depression.
Scrip - July 7, 2026

Kao USA Recalls Select Oribe Shampoos In US, Canada
Kao USA has voluntarily recalled select lots of Oribe Serene Scalp Densifying Shampoo in the US and Canada after detecting Pluralibacter gergoviae, a bacterium that can pose a risk to immunocompromised individuals.
HBW Insight - July 7, 2026

Cyllene Cements Slot In HSV-1 Gene Therapy Space With €33m Cash Boost
The French firm’s series C financing is backed by Merck KGaA’s M Ventures.
Scrip - July 7, 2026

Pancreatic Cancer And China Adjustments Fuel Q2’s Mid-Cap Moves
Erasca and Tango Therapeutics have emerged as potential future players in pancreatic cancer, while declines in select South Korea and China stocks belie an otherwise rapidly-growing sector.
Scrip - July 7, 2026

EU Tests Drug-Diagnostic Partnerships In Unified Pathway Pilot
An ongoing pilot will test whether a single pathway for combined drug and diagnostic/device studies works with products developed by separate companies.
Medtech Insight - July 7, 2026

Alcon Bets Up To $200m On Tunable IOLs In RxSight Collaboration
Alcon will license RxSight's light-adjustable technology in a non-exclusive deal worth up to $200m to co-develop tunable presbyopia-correcting IOLs, paying $60m upfront.
Medtech Insight - July 7, 2026

Treat Now, Pay Later: How Immuneel Hopes To Unlock CAR-T Access In India
Immuneel offers zero cost EMI program for its CAR-T cell therapy in India. Can the model meaningfully scale access or improve treatment initiation rates, as seen in similar prior big pharma initiatives?
Scrip - July 7, 2026

Stock Watch: Japan, The Land Of The Falling Drug Revenues
Second-quarter Japanese yen weakness against the US dollar may push the former second-largest pharma market further down the league tables with implications for the quarterly results of companies operating there.
Scrip - July 7, 2026

Apotex And Cumberland Deal Reaches Completion
Canadian pharma giant Apotex has successfully completed its acquisition of Cumberland Pharmaceutical’s US branded businesses.
Generics Bulletin - July 7, 2026

Towa Adds Tanabe Capacity To Stabilize Off-Patent Supply
Towa’s deal for Tanabe Pharma Factory adds owned capacity, 35 product approvals and originator know-how, extending a wider strategy to shore up Japan’s off-patent medicines supply through acquisitions, outsourcing and backup production.
Generics Bulletin - July 7, 2026

Alvotech Seeks Launch Momentum From Renewed FDA Push
After betting early on streamlined biosimilar development and first-wave assets, Alvotech is now trying to turn foresight into approvals, launches and access, Róbert Wessman says in an exclusive interview with Generics Bulletin.
Generics Bulletin - July 7, 2026

Execs On The Move: June 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - July 7, 2026

Tanabe Divests Plants To Towa, Focuses On R&D And Japan Market
Tanabe transfers its Japan manufacturing subsidiary and 17 products to Towa to concentrate resources on Japan-centric R&D and business development across CNS, oncology, immune and rare disease categories.
Scrip - July 7, 2026

AstraZeneca Rekindles EGFR-TKI/PD-L1 Approach In NSCLC
UK major partners with Abbisko for a China trial of a combo of Tagrisso and Chinese firm’s potential first-in-class oral PD-L1 inhibitor.
Scrip - July 7, 2026

Cancer Drug Suppliers In Limelight As Oxaliplatin Added To US List Of Shortages
Oncology drug suppliers like Fresenius Kabi, Sandoz, Teva, Dr. Reddy’s and Aurobindo are in the spotlight as they hold keys to solving a deepening cancer drugs shortage crisis in US, EU, Australia, Canada and India, amid originator brand discontinuations and structural issues.
Generics Bulletin - July 7, 2026

Inside AbbVie’s Biology-First ADC Strategy
As the antibody-drug conjugate field expands rapidly, AbbVie has quietly assembled one of oncology's largest ADC pipelines while pursuing a strategy centred on matching treatments to patient biology.
In Vivo - July 7, 2026

US FDA Readies Hemp Products Rule With Tighter THC Limits Imposed By Congress Approaching
Congress waits for report it requested in November 2025 identifying the varieties of cannabinoids as Nov. 12 effective date approaches for a lower limit, included in the same legislation, on all forms of THC allowed in hemp products and a ban on synthetics.
HBW Insight - July 7, 2026

Coty Initiates Organization Changes, Takasago Taps New President; Beauty Business Roundup
Coty announces structural changes that place decision-making “closer to the center,” while Japanese flavors and fragrance company Takasago names a new president and dsm-firmenich promotes two master perfumers.
HBW Insight - July 7, 2026

Vertex Grows Its Rare Disease Business With $10bn Crinetics Buy
Vertex will pay $85 per share for Crinetics, which is double the company’s July 6 closing stock price, to acquire what it sees as a blockbuster endocrinology franchise.
Scrip - July 7, 2026